PharmaPoint: Hepatitis C Virus – Japan Drug Forecast and Market Analysis to 2022

Publisher Name :
Date: 31-May-2013
No. of pages: 130

Summary

GlobalData has released its new Country report, “PharmaPoint: Hepatitis C Virus – Japan Drug Forecast and Market Analysis to 2022″. Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roche’s Pegasys and Merck’s PegIntron) and ribavirin (e.g., Roche’s Copegus and Merck’s Rebetol) are used to treat HCV infection. Patients infected with HCV genotype 1 can also have a protease inhibitor added to their combination therapy, such as Merck’s Victrelis (boceprevir) or Vertex’s Incivek (telaprevir). The entrance of next-generation HCV therapies is expected to fundamentally change the HCV treatment algorithm. GlobalData expects a dramatic shift favoring the uptake of interferon-free regimens due to their more tolerable side-effect profiles and decreased duration of therapy compared with the current standard of care.

The projected drivers of market growth in Japan include the launch of next-generation HCV regimens, increasing awareness of HCV, and a shift toward preventative care of HCV.

Merck’s PegIntron (peginterferon alfa-2b) is the current market leader in Japan. The current standard of HCV therapy in Japan is a combination of interferon and ribavirin. The less-frequent dosing of peginterferon compared with standard interferon (i.e., once a week compared with three times a week) enabled peginterferon to quickly capture market share. In addition to standard interferon, PegIntron directly competes for market share with Roche’s Pegasys (peginterferon alfa-2a). GlobalData’s primary research revealed that peginterferon market position is further bolstered by the frequent use of interferon monotherapy in Japan.

Scope

  • Overview of the HCV including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Japan from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting Japan HCV market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for HCV
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in Japan

PharmaPoint: Hepatitis C Virus – Japan Drug Forecast and Market Analysis to 2022

Table Of Contents

1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 9

2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 10
2.3 Upcoming Related Reports 11

3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 16
3.1.3 Prognosis 17
3.2 Symptoms 17

4 Disease Management 18
4.1 Diagnosis and Referral Overview 18
4.2 Treatment Overview 19
4.3 Japan 21
4.3.1 Diagnosis 21
4.3.2 Clinical Practice 22

5 Competitive Assessment 23
5.1 Overview 23
5.2 Strategic Competitor Assessment 23
5.3 Product Profiles - Major Brands 25
5.3.1 Incivek (telaprevir) 25
5.3.2 Pegasys (peginterferon alfa-2a) 30
5.3.3 PegIntron (peginterferon alfa-2b) 34
5.3.4 Copegus, Rebetol, and Generic Ribavirin 38
5.3.5 Therapeutic Class: Interferon 40

6 Opportunity and Unmet Need 41
6.1 Overview 41
6.2 Unmet Needs 42
6.2.1 Unmet Need: Treatment Tolerability 42
6.2.2 Unmet Need: Efficacy 42
6.2.3 Unmet Need: Disease Awareness 43
6.2.4 Unmet Need: Treatment Cost 44
6.2.5 Unmet Need: Shorter Treatment Duration 44
6.2.6 Unmet Need: Simplified Treatment Regimens 45
6.3 Unmet Needs Gap Analysis 45
6.4 Opportunities 46
6.4.1 Opportunity: Pan-genotypic HCV Regimen 46
6.4.2 Opportunity: Treatment of Underrepresented Patient Populations 46
6.4.3 Opportunity: Involvement of Immune System 47

7 Pipeline Assessment 48
7.1 Overview 48
7.2 Promising Drugs in Clinical Development 49
7.2.1 Sofosbuvir and Sofosbuvir/Ledipasvir 51
7.2.2 Simeprevir 60
7.2.3 ABT-450 plus ABT-267 and ABT-333 67
7.2.4 Faldaprevir and Faldaprevir plus BI 207127 74
7.2.5 Daclatasvir and Daclatasvir plus Asunaprevir 82
7.2.6 Vaniprevir 89
7.2.7 Other Drug Classes 94

8 Market Outlook 98
8.1 Japan 98
8.1.1 Forecast 98
8.1.2 Key Events 104
8.1.3 Drivers and Barriers 104

9 Appendix 107
9.1 Bibliography 107
9.2 Abbreviations 115
9.3 Methodology 117
9.4 Forecasting Methodology 117
9.4.1 Percent Drug-Treated Patients 117
9.4.2 Patient Warehousing 118
9.4.3 Drugs Included in Each Therapeutic Class 118
9.4.4 Launch and Patent Expiry Dates 119
9.4.5 General Pricing Assumptions 120
9.4.6 Individual Drug Assumptions 120
9.4.7 Generic Erosion 122
9.4.8 Selection of Pipeline Agents 122
9.4.9 Pricing of Pipeline Agents 123
9.5 Physicians and Specialists Included in this Study 126
9.6 Survey of Prescribing Physicians 128
9.7 About the Authors 129
9.7.1 Author 129
9.7.2 Global Head of Healthcare 129
9.8 About GlobalData 130
9.9 Contact Us 130
9.10 Disclaimer 130

List Of Tables

Table 1: Modes of HCV Transmission 16
Table 2: Symptoms of Acute and Chronic HCV Infection 17
Table 3: HCV Genotypes Present in the 9MM 19
Table 4: General Standard of Care by HCV Genotype 19
Table 5: Treatment Guidelines for HCV by Country 20
Table 6: Most-Prescribed Drugs for HCV by Class in the Global Markets, 2013 21
Table 7: Leading Treatments for HCV, 2012 24
Table 8: Product Profile - Incivek 26
Table 9: Efficacy of Incivek in Treatment-Naïve Patients (ADVANCE Trial) 26
Table 10: Efficacy of Incivek in Treatment-Experienced Patients (REALIZE Trial) 27
Table 11: Common Incivek Adverse Drug Reactions 28
Table 12: Incivek SWOT Analysis, 2012 29
Table 13: Product Profile - Pegasys 31
Table 14: Antiviral Efficacy of Peginterferon alfa-2a Compared with Interferon alfa-2b 32
Table 15: Pegasys SWOT Analysis, 2012 34
Table 16: Product Profile - PegIntron 35
Table 17: Antiviral Efficacy of Peginterferon alfa-2b Compared with Interferon alfa-2b 36
Table 18: PegIntron SWOT Analysis, 2012 37
Table 19: Effect of Addition of Ribavirin to Peginterferon HCV Therapy 39
Table 20: Ribavirin SWOT Analysis, 2012 40
Table 21: Summary of Minor Therapeutic Classes, 2012 40
Table 22: Overall Unmet Needs - Current Level of Attainment 41
Table 23: Clinical Unmet Needs - Gap Analysis, 2012 45
Table 24: HCV - Pipeline, 2012 49
Table 25: Comparison of Therapeutic Classes in Development for HCV, 2012 50
Table 26: Gilead's Sofosbuvir Ongoing Clinical Trials of Interest 52
Table 27: Product Profile - Sofosbuvir 53
Table 28: Sofosbuvir's Most Common Adverse Effects 56
Table 29: Sofosbuvir SWOT Analysis, 2012 60
Table 30: Janssen's Simeprevir Ongoing Clinical Trials of Interest 61
Table 31: Product Profile - Simeprevir 62
Table 32: PILLAR Clinical Trial Results 62
Table 33: Adverse Events Observed in PILLAR Clinical Trial 63
Table 34: Simeprevir SWOT Analysis, 2012 67
Table 35: AbbVie's Combination Therapy Ongoing Clinical Trials of Interest 68
Table 36: Product Profile - AbbVie Combination Therapy 69
Table 37: AVIATOR Clinical Trial Results 69
Table 38: AbbVie Combination Therapy SWOT Analysis, 2012 73
Table 39: Boehringer Ingelheim's Faldaprevir Ongoing Clinical Trials of Interest 75
Table 40: Product Profile - Faldaprevir 76
Table 41: Efficacy of Interferon-Free Faldaprevir Regimen (SOUND-C2 Trial) 77
Table 42: Faldaprevir SWOT Analysis, 2012 81
Table 43: Bristol-Myers Squibb's Daclatasvir Ongoing Clinical Trials of Interest 83
Table 44: Product Profile - Daclatasvir 84
Table 45: Efficacy of Daclatasvir in Treatment-Naïve Patients (COMMAND-1 Trial) 84
Table 46: Daclatasvir and Asunaprevir Quad Therapy Efficacy 85
Table 47: Daclatasvir Triple Therapy Adverse Events 86
Table 48: Daclatasvir SWOT Analysis, 2012 89
Table 49: Merck's Vaniprevir Ongoing Clinical Trials of Interest 90
Table 50: Product Profile - Vaniprevir 90
Table 51: Vaniprevir SWOT Analysis, 2012 94
Table 52: Comparison of Peginterferon lambda with Peginterferon alfa (EMERGE Trial) 95
Table 53: Efficacy of Alisporivir in Treatment-Naïve HCV GT2/3 Patients (VITAL-1 Trial) 96
Table 54: Sales Forecasts ($m) for HCV in Japan, 2012-2022 101
Table 55: Key Events Impacting Sales for HCV in Japan, 2012 104
Table 56: Japanese HCV Market - Drivers and Barriers, 2012 104
Table 57: Key Launch Dates 119
Table 58: Key Patent Expiries 119
Table 59: Physicians Surveyed, By Country 128

List Of Figures

Figure 1: HCV Genome and Polyprotein Composition 13
Figure 2: HCV Lifecycle Overview 14
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in HCV, 2012-2022 49
Figure 4: Sales for HCV Therapeutics in Japan by Drug Class, 2012-2022 103

  • Challenges in the Tourism Industry in Thailand
    Thailand has always been a popular tourist destination and tourism provides a major boost to the country’s economy. Bangkok, Hua Hin, Krabi, Samui, Phuket and Cha Am are some of the most attractive tourist destinations in the country. In 2012, Thailand had a very high number of arrivals. Even the number of Thai citizens who [...]
  • Future of the US Consumer Electronics Market
    The market for consumer electronics has been growing steadily. Some of the factors that are contributing to the growth in the market are technological advancement, rise in disposable income and increasing demand for new products. During 2012, consumer electronics market in the US demonstrated positive expansion, although the growth rate slowed down considerably following the [...]
  • Overview of the Global Retail Market
    The global retail industry continued to grow despite the difficult economic conditions in the world. In the fiscal year of 2011, sales-weighted, currency-adjusted revenue rose by 5.1% to $4.271 trillion for the world’s top 250 retailers. According to GRDI (Global Retail Development Index), in 2013 Brazil occupied the top spot in retail development. Chile and [...]
  • Bright Future Predicted for the Tourism Industry in Singapore
    Travel and tourism industry in Singapore has been growing at a steady rate and is considered to be a major contributor to the economic growth of the country. In 2012, Singapore’s IVA (International Visitors Arrivals) reached a record high of 14.5 million, with a growth rate of 10.1% year-on-year. In recent years, inbound travel to [...]
  • Potential of Staffing Market in United States
    The staffing industry places individuals into contract, temporary and permanent positions in firms around the world. Major staffing markets include France, Spain, Italy and Japan as well as many emerging markets. Temporary staffing around the world has been growing, but in US temporary market has been flat since 2006. The majority of staffing revenue majorly [...]
  • Graft-Versus-Host Disease (GVHD) Treatment Market worth $407 million by 2018
  • The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm GlobalData. The company’s latest report* states …

  • Poland Pharmaceutical Industry Growing at 8.3% CAGR to 2020
  • Factors such as the growing elderly population, increasing availability of affordable medicines, and transparent regulatory guidelines will provide the necessary impetus for the growth of the Polish pharmaceutical market, but a decrease in mark-up prices and the country’s stringent drug …

  • Asia-Pacific, Led by China, Drive the Global Methanol Industry
  • China is driving the global methanol industry, with tremendous demand from both its energy and petrochemicals sectors. It accounts for 87.9% of Asia-Pacific’s (APAC) methanol capacity, and 51.9% of the global methanol capacity. Despite a large planned capacity increase in …

  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Graft-Versus-Host Disease Market Forecast to 2023
  • Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either …

  • 2014 Deep Research Report on Global and China Naltrexone HCL Industry
    Published: 28-Oct-2014        Price: US $2200 Onwards        Pages: 138
    This is a professional and depth research report on Global Naltrexone HCL industry. The report firstly introduced Naltrexone HCL basic information included Naltrexone HCL definition classification application industry chain structure industry overview; international market analysis, China domestic market analysis. Global Regional (such as US Europe Asia China Japan etc regions) Global Leading Suppliers, different type products, different applications etc Naltrexone HCL production and market shar......
  • Global ADHD Drugs Market 2014-2018
    Published: 22-Oct-2014        Price: US $2500 Onwards        Pages: 80
    ADHD is a psychiatric disorder, which is mostly found in children. However, adults have also been reported to be diagnosed with ADHD. The patients with ADHD suffer from several problems including hyperactivity, impulsiveness, and lack of focus and concentration. The causes of ADHD are not known. It is believed to be linked with genetic and environmental causes. However, it has been reported to be related with the decrease in the extraneuronal levels of norepinephrine and dopamine. In addition, t......
  • Global Huntington’s Disease Therapeutics Market 2014-2018
    Published: 22-Oct-2014        Price: US $2500 Onwards        Pages: 72
    Huntington's disease is a progressive neurodegenerative disorder that can be inherited from one generation to another as an autosomal dominant trait. It arises due to genetically programmed degeneration of neurons in some parts of the brain such as basal ganglia and cerebral cortex. Basal ganglia plays an important role in coordinating movement while cerebral cortex regulates perception, thought, and memory. Degeneration of neurons leads to progressive cognitive impairment and dementia. People w......
  • Global Pediatric Vaccine Market 2014-2018
    Published: 22-Oct-2014        Price: US $2500 Onwards        Pages: 85
    Pediatric vaccines are used for the immunization of children and adolescents against various infectious diseases, such as diphtheria, influenza, hepatitis, pneumococcal diseases, and meningococcal diseases. According to the US FDA, pediatric age ranges are classified as newborn, infant, child, and adolescent, ranging from birth to 21 years. However, the EMA classifies pediatric age range from birth to 18 years. TechNavio's analysts forecast the Global Pediatric Vaccine market to grow at a CAG......
  • Insulin Market in China 2014-2018
    Published: 22-Oct-2014        Price: US $2500 Onwards        Pages: 78
    Insulin is a hormone produced in the pancreas. It regulates the metabolism of glucose and other nutrients in the body. Insulin permits the body to utilize sugar (glucose) from carbohydrates in the food for energy or to store glucose for future use. Various types of insulin exist depending on how quickly they work, when they peak, and how long they last. In diabetic condition, the pancreas no longer produces adequate insulin or the cells stop responding to the insulin that is produced, leading to......
  • Major Depressive Disorder Therapeutics in Major Developed Markets to 2020 – New Launches and Modest Uptake of New Adjunctive Treatments to Offset Patent Expiries
    Published: 1-Oct-2014        Price: US $4995 Onwards        
    GBI Research, the leading business intelligence provider, has released its latest research, ‘Major Depressive Disorder Therapeutics in Major Developed Markets to 2020 - New Launches and Modest Uptake of New Adjunctive Treatments to Offset Patent Expiries’, which provides insights into Major Depressive Disorder (MDD) in the major developed markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an estimation of market size for 2013, along with market fo......
  • Penicillin Markets in China
    Published: 1-Oct-2014        Price: US $4000 Onwards        Pages: 190
    China's demand for Penicillin has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry......
  • Global H1N1 Vaccines Market 2014-2018
    Published: 1-Oct-2014        Price: US $2500 Onwards        Pages: 66
    H1N1 influenza (zoonotic) is an infectious disease in humans caused by a variant of the swine H1N1 virus, known as H1N1v virus. The H1N1v virus is a contagious virus which infects nose, throat, and lungs. H1N1 virus is an RNA virus belonging to the Orthomyxoviridae family. Influenza A viruses infect different animal species such as humans, swine, birds, seals, and horses. Influenza A viruses can be subdivided on the basis of antigenicity of its surface glycoproteins neuraminidase and hemagglutin......
  • PharmaPoint: HER2-Positive Breast Cancer – China Drug Forecast and Market Analysis to 2023
    Published: 30-Sep-2014        Price: US $4995 Onwards        Pages: 154
    HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third-, and fourth-line metastatic. Currently, treatment rates for HER2-positive breast cancer in China are low, with......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs